conjugate,

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-ConceptCallio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird BioscienceFinancing…

2 months ago
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug ConjugateRadiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced…

2 months ago
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqorys TROP2 Antibody Drug Conjugate, OQY-3258Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqorys TROP2 Antibody Drug Conjugate, OQY-3258

Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqorys TROP2 Antibody Drug Conjugate, OQY-3258

SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address…

3 months ago